CLClinicLens

Unclassified

Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian

In advanced EGFR-mutant non-small cell lung cancer (NSCLC) after EGFR-TKI failure, chemotherapy alone offers limited benefit, while heterogeneous efficacy and safety across combination regimens complicate treatment selection. We systematically compared chemotherapy-anchored regim

Medical Literature · Updated

← Back to articles
This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.